Company intelligence / Profile preview

Synowlwedge

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Synowlwedge is a pre-clinical stage biotechnology company focused on developing novel therapeutics for synucleinopathies, including Parkinson's disease and Multiple System Atrophy. The company utilizes a proprietary platform to identify and develop small molecule inhibitors that specifically target the pathological aggregation of alpha-synuclein. By preventing the formation of toxic protein clumps, Synowlwedge aims to provide disease-modifying treatments for neurodegenerative disorders. Their approach focuses on high-affinity binding to misfolded protein species to halt disease progression.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Synowlwedge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synowlwedge.

Explore the full profile